Home › Research › Long-term cohort studies
Exploring the effect of pre-clinical Alzheimer’s disease on blood pressure using Mendelian randomisation and parental dementia as an instrumental variable in UK Biobank
Jennifer C Palmer, Emma C. Hart, Emma Louise Anderson, Seth Love, Deborah A. Lawlor. BMC Medicine, 2025-08-19
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Both the higher parental dementia instrument and participant genetic instrument score were associated with higher mean SBP (difference in mean SBP mmHg per 1SD higher score: 0.12, 95% CI 0.06 to 0.17, p < 0.0001, and 0.07, 95% CI 0.00 to 0.13, p=0.037, respectively) but not DBP. Sensitivity analyses were largely consistent with these findings. Our findings provide preliminary evidence that pre-clinical AD increases SBP. Further research is required to determine whether this increase in SBP is due to increased cerebrovascular resistance as a result of pre-clinical AD. Obtaining a better understanding of the changing relationship with BP at different stages of AD may enable effective optimisation and targeting of therapies.
What this study adds
Evidence grade: Low
The record lists 501,420 participants. Using Mendelian randomisation and parental dementia as an instrument, the authors found preliminary evidence that pre-clinical Alzheimer's disease increases systolic blood pressure. They call for further research to understand how blood pressure changes across stages of the disease, which could help target therapies.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Palmer, J. C., Hart, E. C., Anderson, E. L., Love, S., & Lawlor, D. A. (2025). Exploring the effect of pre-clinical Alzheimer’s disease on blood pressure using Mendelian randomisation and parental dementia as an instrumental variable in UK Biobank. BMC Medicine. https://doi.org/10.1186/s12916-025-04295-5
Vancouver
Palmer JC, Hart EC, Anderson EL, Love S, Lawlor DA. Exploring the effect of pre-clinical Alzheimer’s disease on blood pressure using Mendelian randomisation and parental dementia as an instrumental variable in UK Biobank. BMC Medicine. 2025. doi:10.1186/s12916-025-04295-5. PMID: 40830462.
BibTeX
@article{palmer2025-40830462,
author = {Palmer, Jennifer C and Hart, Emma C. and Anderson, Emma Louise and Love, Seth and Lawlor, Deborah A.},
title = {{Exploring the effect of pre-clinical Alzheimer’s disease on blood pressure using Mendelian randomisation and parental dementia as an instrumental variable in UK Biobank}},
journal = {BMC Medicine},
year = {2025},
doi = {10.1186/s12916-025-04295-5},
pmid = {40830462},
url = {https://doi.org/10.1186/s12916-025-04295-5}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Both the higher parental dementia instrument and participant genetic instrument score were associated with higher mean SBP (difference in mean SBP mmHg per 1SD higher score: 0.12, 95% CI 0.06 to 0.17, p < 0.0001, and 0.07, 95% CI 0.00 to 0.13, p=0.037, respectively) but not DBP.
- Sensitivity analyses were largely consistent with these findings.
- Our findings provide preliminary evidence that pre-clinical AD increases SBP.
- Further research is required to determine whether this increase in SBP is due to increased cerebrovascular resistance as a result of pre-clinical AD.
- Obtaining a better understanding of the changing relationship with BP at different stages of AD may enable effective optimisation and targeting of therapies.
Why it matters
Using Mendelian randomisation and parental dementia as an instrument, the authors found preliminary evidence that pre-clinical Alzheimer's disease increases systolic blood pressure. They call for further research to understand how blood pressure changes across stages of the disease, which could help target therapies.
Study details
- Participants501,420
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 41 of the 96 points we could judge it on, which is 43 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (BMC Medicine) |
| Journal's citation record | 3 / 4 | BMC Medicine: journal h-index 259 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 4 / 4 | 501,420 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 1 / 3 | University of Bristol: institution h-index 1,260 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40830462) |
| Free to read | 2 / 2 | Free to read |
| Points | 41 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 41 of the 96 points we could judge it on is 43 out of 100. |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 17.
Related studies in Long-term cohort studies from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.